IM Cannabis Corp. (NASDAQ: IMCC) (CSE: IMCC) - Investor Dashboard
|Employees:||200 as of 4/26/21|
IM Cannabis – Multinational Facilities
IMC plans to bring its premium products to medical patients and adult-use consumers around the world through continued expansion of its global presence. The company will accomplish this goal through a measured and purposeful acquisition strategy.
As one of the global medical cannabis industry pioneers, the IMC brand was launched back in 2010 in Israel, the modern-era bedrock of cannabinoid-based therapies and medical cannabis research. Focus Medical, one of eight original licensed producers of medical cannabis in Israel, has been cultivating IC branded cannabis for over 10 years, growing high quality medical cannabis in the Israeli market. Focus Medical has an exclusive commercial agreement with IMC to distribute its production under the IMC brand. In addition to its own capacity, Focus Medical has supply agreements with six other cultivators for additional supply using its proprietary genetics and for sale under the IMC brand.
IMC’s primary European center of operations is in Germany, the largest and most advanced legal Cannabis market outside of North America and Israel. The German-based IMC subsidiary, Adjupharm GmbH, is an EU-GMP certified medical cannabis and pharmaceutical distributor which acts as the Company’s European hub and a gateway for future continent expansion. With an on-the-ground presence in the German market, the Company’s branded medical cannabis products are already being distributed to pharmacies, prescribed by physicians, and used by patients across Germany, further establishing IMC as a global brand.
IMC’s European presence is also augmented through strategic alliances with EU-GMP certified suppliers and distributors across the continent. This network provides IMC with the additional breadth, depth and scalability required to expand in Germany and throughout Europe as more jurisdictions move toward cannabis market reforms.
As IMC’s third geographical pillar, the company has extended its Canadian market footing through the acquisition of Canadian-based Trichome Financial Corp. This acquisition enhances IMC’s operational presence in Canada across various dimensions. It provides the Company with an advanced indoor cultivation and processing facility that diversifies IMC’s supply sources to local and international markets and adds an interprovincial distribution network for selling the Company’s products in the legal adult-use recreational and medical cannabis segments.
Furthermore, the acquisition of Trichome enhances IMC leadership’s bench strength thanks to the addition of a seasoned Canadian management team with M&A and restructuring expertise to further drive the Company’s growth in one of the world’s top three legal cannabis markets.
The team’s first acquisition is MYM Nutraceuticals Inc. and its licensed producer subsidiary, Highland Grow Inc., a deal which is expected to close in the 2nd half of 2021.
New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. IM Cannabis Corp. is a client of NCV Media, LLC. Read our full disclaimer.